Тезисы 2021 год
Тезисы, опубликованные в периодических изданиях
- Ionova T.I., Andrievskikh M.I., Amdiev A.A., Baryakh E.A., Chang V.L., Еndakova A.I., Fadeeva N.V., Husainova G.N., Ivanov V.V., Kaplanov K.D., Kaverina O.V., Kiseleva M.Ya., Klitochenko T.Yu., Kurakin V.I., Larionova O.G., Lazareva D.G., Lepik K.V., Lysenko I.B., Melnichenko V.Ya, Mikhailova N.B., Minullina R.I., Mironov O.V., Misyurina E.N., Mochkin N.Eu., Nikitina T.P., Osipov Iu.S., Petrova T.S., Porfirieva N.M., Rukavitsyn O.A., Safin R.N., Samoilova A.A., Shelekhova T.V., Sherstnev D.G., Simashova P.I., Smirnova E.G., Trenina N.A., Vasiliev Eu.V., Volkov M.V., Volodicheva E.M. Outcomes of brentuximab vedotin as ?3 line treatment in patients with relapsed/refractory classical Hodgkin lymphoma: physician’s and patient’s perspective. HemaSphere. 2021; 5, S2: 572.
- Ionova T.I., Andrievskikh M.I., Amdiev A.A., Baryakh E.A., Chang V.L., Еndakova A.I., Fadeeva N.V., Husainova G.N., Ivanov V.V., Kaplanov K.D., Kaverina O.V., Kiseleva M.Ya., Klitochenko T.Yu., Kurakin V.I., Larionova O.G., Lazareva D.G., Lepik K.V., Lysenko I.B., Melnichenko V.Ya, Mikhailova N.B., Minullina R.I., Mironov O.V., Misyurina E.N., Mochkin N.Eu., Nikitina T.P., Osipov Iu.S., Petrova T.S., Porfirieva N.M., Rukavitsyn O.A., Safin R.N., Samoilova A.A., Shelekhova T.V., Sherstnev D.G., Simashova P.I., Smirnova E.G., Trenina N.A., Vasiliev Eu.V., Volkov M.V., Volodicheva E.M. Brentuximab vedotin for treatment in patients with relapsed/refractory classical Hodgkin lymphoma in a real world setting: clinical outcomes and impact on quality of life. Hematological Oncology. 2021; 39 (Issue S2): 442–443.
- Laane E., Ionova T., Oliva E.N., Andreas M., Kreuzberger N., Piechotta V. et al. Appraisal of the consistent use and reporting of patient-reported outcomes in multiple myeloma clinical trials: Does it matter? HemaSphere. 2021; 5(SUPPL 2): 570.
- Andreas M, Salek S, Kreuzberger N, Piechotta V, Oliva EN, Ionova T. I., Monsef I., Skoetz N., Laane E. Patient-reported outcomes in clinical trials for multiple myeloma: Where we are. Journal of Clinical Oncology, 2021; 39(15): e18615-e18615.
|
